175 related articles for article (PubMed ID: 32864713)
1. The clonal evolution during long-term clinical course of multiple myeloma.
Mishima Y; Mishima Y; Shirouchi Y; Nishimura N; Yokoyama M; Okabe T; Inoue N; Uryu H; Fukuta T; Hatake K; Terui Y
Int J Hematol; 2021 Feb; 113(2):279-284. PubMed ID: 32864713
[TBL] [Abstract][Full Text] [Related]
2. Clonal Evolution in Multiple Myeloma.
Fakhri B; Vij R
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S130-4. PubMed ID: 27521309
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma clonal evolution in homogeneously treated patients.
Corre J; Cleynen A; Robiou du Pont S; Buisson L; Bolli N; Attal M; Munshi N; Avet-Loiseau H
Leukemia; 2018 Dec; 32(12):2636-2647. PubMed ID: 29895955
[TBL] [Abstract][Full Text] [Related]
4. Myeloid transformation of plasma cell myeloma: molecular evidence of clonal evolution revealed by next generation sequencing.
Gralewski JH; Post GR; van Rhee F; Yuan Y
Diagn Pathol; 2018 Feb; 13(1):15. PubMed ID: 29463311
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Kortüm KM; Langer C; Monge J; Bruins L; Zhu YX; Shi CX; Jedlowski P; Egan JB; Ojha J; Bullinger L; Kull M; Ahmann G; Rasche L; Knop S; Fonseca R; Einsele H; Stewart AK; Braggio E
Ann Hematol; 2015 Jul; 94(7):1205-11. PubMed ID: 25743686
[TBL] [Abstract][Full Text] [Related]
6. Monitoring multiple myeloma by quantification of recurrent mutations in serum.
Rustad EH; Coward E; Skytøen ER; Misund K; Holien T; Standal T; Børset M; Beisvag V; Myklebost O; Meza-Zepeda LA; Dai HY; Sundan A; Waage A
Haematologica; 2017 Jul; 102(7):1266-1272. PubMed ID: 28385781
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for multiple myeloma in the era of novel therapies.
Ziogas DC; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2018 Nov; 11(11):863-879. PubMed ID: 30334460
[TBL] [Abstract][Full Text] [Related]
8. Advances in understanding prognosis in myeloma.
Smith D; Yong K
Br J Haematol; 2016 Nov; 175(3):367-380. PubMed ID: 27604166
[TBL] [Abstract][Full Text] [Related]
9. Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma.
Rustad EH; Misund K; Bernard E; Coward E; Yellapantula VD; Hultcrantz M; Ho C; Kazandjian D; Korde N; Mailankody S; Keats JJ; Akhlaghi T; Viny AD; Mayman DJ; Carroll K; Patel M; Famulare CA; Op Bruinink DH; Hutt K; Jacobsen A; Huang Y; Miller JE; Maura F; Papaemmanuil E; Waage A; Arcila ME; Landgren O
Am J Hematol; 2019 Dec; 94(12):1364-1373. PubMed ID: 31571261
[TBL] [Abstract][Full Text] [Related]
10. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
11. Revised International Staging System Applied to Real World Multiple Myeloma Patients.
Jimenez-Zepeda VH; Duggan P; Neri P; Rashid-Kolvear F; Tay J; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):511-518. PubMed ID: 27425179
[TBL] [Abstract][Full Text] [Related]
12. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
Egan JB; Shi CX; Tembe W; Christoforides A; Kurdoglu A; Sinari S; Middha S; Asmann Y; Schmidt J; Braggio E; Keats JJ; Fonseca R; Bergsagel PL; Craig DW; Carpten JD; Stewart AK
Blood; 2012 Aug; 120(5):1060-6. PubMed ID: 22529291
[TBL] [Abstract][Full Text] [Related]
13.
Boyle EM; Ashby C; Tytarenko RG; Deshpande S; Wang H; Wang Y; Rosenthal A; Sawyer J; Tian E; Flynt E; Hoering A; Johnson SK; Rutherford MW; Wardell CP; Bauer MA; Dumontet C; Facon T; Thanendrarajan S; Schinke CD; Zangari M; van Rhee F; Barlogie B; Cairns D; Jackson G; Thakurta A; Davies FE; Morgan GJ; Walker BA
Clin Cancer Res; 2020 May; 26(10):2422-2432. PubMed ID: 31988198
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis beyond the cancer clone(s) in multiple myeloma.
Bianchi G; Munshi NC
Blood; 2015 May; 125(20):3049-58. PubMed ID: 25838343
[TBL] [Abstract][Full Text] [Related]
15. The molecular spectrum and clinical impact of DIS3 mutations in multiple myeloma.
Weißbach S; Langer C; Puppe B; Nedeva T; Bach E; Kull M; Bargou R; Einsele H; Rosenwald A; Knop S; Leich E
Br J Haematol; 2015 Apr; 169(1):57-70. PubMed ID: 25521164
[TBL] [Abstract][Full Text] [Related]
16. Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays.
Coombs CC; Gillis NK; Tan X; Berg JS; Ball M; Balasis ME; Montgomery ND; Bolton KL; Parker JS; Mesa TE; Yoder SJ; Hayward MC; Patel NM; Richards KL; Walko CM; Knepper TC; Soper JT; Weiss J; Grilley-Olson JE; Kim WY; Earp HS; Levine RL; Papaemmanuil E; Zehir A; Hayes DN; Padron E
Clin Cancer Res; 2018 Dec; 24(23):5918-5924. PubMed ID: 29866652
[TBL] [Abstract][Full Text] [Related]
17. How to Think About Risk in Myeloma.
Krishnan A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S135-8. PubMed ID: 27521310
[TBL] [Abstract][Full Text] [Related]
18. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.
Weinhold N; Ashby C; Rasche L; Chavan SS; Stein C; Stephens OW; Tytarenko R; Bauer MA; Meissner T; Deshpande S; Patel PH; Buzder T; Molnar G; Peterson EA; van Rhee F; Zangari M; Thanendrarajan S; Schinke C; Tian E; Epstein J; Barlogie B; Davies FE; Heuck CJ; Walker BA; Morgan GJ
Blood; 2016 Sep; 128(13):1735-44. PubMed ID: 27516441
[TBL] [Abstract][Full Text] [Related]
19. Current Review on High-Risk Multiple Myeloma.
Chan HSH; Chen CI; Reece DE
Curr Hematol Malig Rep; 2017 Apr; 12(2):96-108. PubMed ID: 28317082
[TBL] [Abstract][Full Text] [Related]
20. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma.
Martello M; Poletti A; Borsi E; Solli V; Dozza L; Barbato S; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Vigliotta I; Rizzello I; Rocchi S; Armuzzi S; Testoni N; Marzocchi G; Martinelli G; Cavo M; Terragna C
Blood Cancer J; 2022 Jan; 12(1):15. PubMed ID: 35082295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
